Smead Capital Management Inc. Has $72.95 Million Holdings in Merck & Co., Inc. (MRK)
Smead Capital Management Inc. cut its position in Merck & Co., Inc. (NYSE:MRK) by 2.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,028,385 shares of the company’s stock after selling 27,597 shares during the quarter. Merck & Co., Inc. comprises about 3.3% of Smead Capital Management Inc.’s portfolio, making the stock its 16th largest holding. Smead Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $72,954,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Rockland Trust Co. bought a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $3,949,000. Sawyer & Company Inc raised its stake in Merck & Co., Inc. by 10.7% in the 2nd quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock worth $1,395,000 after purchasing an additional 2,215 shares in the last quarter. Worldquant Millennium Quantitative Strategies LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $23,693,000. Steward Partners Investment Advisory LLC raised its stake in Merck & Co., Inc. by 37.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 122,748 shares of the company’s stock worth $7,451,000 after purchasing an additional 33,153 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Merck & Co., Inc. by 11.0% in the 2nd quarter. Jennison Associates LLC now owns 924,946 shares of the company’s stock worth $56,144,000 after purchasing an additional 91,879 shares in the last quarter. Institutional investors own 72.29% of the company’s stock.
Shares of Merck & Co., Inc. stock opened at $76.35 on Tuesday. The company has a market cap of $205.07 billion, a P/E ratio of 19.18, a P/E/G ratio of 2.07 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.15 and a current ratio of 1.44. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $76.61.
Merck & Co., Inc. declared that its board has initiated a share buyback plan on Thursday, October 25th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 5.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 8th. Shareholders of record on Monday, December 17th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.88%. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.48. The ex-dividend date is Friday, December 14th. Merck & Co., Inc.’s payout ratio is presently 48.24%.
In other news, EVP Julie L. Gerberding sold 36,218 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $75.14, for a total value of $2,721,420.52. Following the sale, the executive vice president now directly owns 82,481 shares of the company’s stock, valued at approximately $6,197,622.34. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Ashley Watson sold 47,036 shares of the company’s stock in a transaction on Wednesday, October 31st. The shares were sold at an average price of $74.33, for a total transaction of $3,496,185.88. Following the completion of the sale, the senior vice president now directly owns 32,990 shares in the company, valued at $2,452,146.70. The disclosure for this sale can be found here. Insiders have sold a total of 1,279,104 shares of company stock worth $92,845,846 over the last three months. Insiders own 0.32% of the company’s stock.
Several brokerages have weighed in on MRK. Citigroup lifted their price objective on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st. BMO Capital Markets lifted their price objective on shares of Merck & Co., Inc. from $70.00 to $82.00 and gave the stock an “outperform” rating in a research note on Monday, October 22nd. ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Wolfe Research began coverage on shares of Merck & Co., Inc. in a research report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Finally, SunTrust Banks boosted their target price on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, October 29th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $72.53.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.